Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment-Reference-Cited by-同舟云学术

Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment

Published:2020-07-12 Issue:6 Volume:38 Page:894-902
ISSN:0914-8779
Container-title:Journal of Bone and Mineral Metabolism
language:en
Short-container-title:J Bone Miner Metab

Author:

Kondo Hideomi^ORCID,Okimoto Nobukazu,Yoshioka Toru,Akahoshi Shojiro,Fuse Yoshifumi,Ogawa Takayuki,Okazaki Yuichi,Katae Yuji,Tsukamoto Manabu,Yamanaka Yoshiaki,Kawasaki Makoto,Sakai Akinori

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Orthopedics and Sports Medicine,General Medicine,Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1007/s00774-020-01126-w.pdf

Reference32 articles.

1. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022

2. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497

3. Sakai A, Ikeda S, Okimoto N, Matsumoto H, Teshima K, Okazaki Y, Fukuda F, Arita S, Tsurukami H, Nagashima M, Yoshioka T (2014) Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study. Osteoporos Int 25:2245–2253

4. Durden Emily, Pinto Lionel, Lopez-Gonzalez Lorena, Juneau Paul, Barron Richard (2017) Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporos 12:22

5. Ziller V, Kostev K, Kyvernitakis I, Boeckhoff J, Hadji P (2012) Persistence and compliance of medications used in the treatment of osteoporosis-analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther 50:315–322

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?;The Journal of Clinical Endocrinology & Metabolism;2024-04-13

2. Bisphosphonates Maintain BMD After Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis;The Journal of Clinical Endocrinology & Metabolism;2024-04-12

3. Letter to the Editor from Mori and Mori: “Sequential Therapy for the Long-Term Treatment of Postmenopausal Osteoporosis”;The Journal of Clinical Endocrinology & Metabolism;2024-02-09

4. Maintenance of bone resorption markers in the low premenopausal range during the year following denosumab discontinuation is associated to bone density preservation. The ReoLaus study;Bone;2023-07

5. Loss of lower extremity bone mineral density 1 year after denosumab is discontinued in persons with subacute spinal cord injury;Osteoporosis International;2023-02-03